Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of intravenous human immunoglobulin in adults and adolescents with primary immune thrombocytopenia
CTR20263792Phase 3Active
- Sponsor
- Guangdong Weilun Biopharmaceutical
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of immune globulin in immune thrombocytopenia (ITP), sponsored by Guangdong Weilun Biopharmaceutical. Started Oct 2026; status: active.
02
Drugs
immune globulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20263792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263792.